FDA Accepts BMS sNDA for Priority Review: Camzyos (mavacamten) in Adolescents with Obstructive HCM
Key Dates
What Happened
The FDA accepted for Priority Review a Bristol Myers Squibb supplemental New Drug Application (sNDA) to expand Camzyos (mavacamten) to adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This is an acceptance for review, not an approval. BMS announced the acceptance on May 29, 2026 (some BMS materials reference June 1). The FDA set a PDUFA target action date of September 30, 2026. The application is supported by the SCOUT-HCM trial (presented at ACC 2026 and published in NEJM). If approved, Camzyos would be the first cardiac myosin inhibitor indicated for adolescents; it is currently approved only for adults.
Who It Affects
Pediatric and adolescent cardiology programs, children's hospitals with cardiomyopathy and inherited cardiac disease clinics, and families managing oHCM in teenagers — a population that currently relies on older symptom-management drugs (beta blockers, calcium channel blockers) and invasive septal reduction. It is also a signal for pediatric specialty-pharma and rare/inherited cardiac disease investors watching whether adult cardiometabolic franchises extend down into adolescent indications.
Business Implications
For maternal-pediatric health tech coverage this is a watch-item, not a settled change: nothing reimburses or prescribes differently until the FDA acts. The signal value is the trajectory. A targeted, mechanism-specific cardiac therapy moving toward an adolescent label expands the addressable pediatric specialty-care market and validates the model of running dedicated pediatric trials (SCOUT-HCM) to extend an established adult drug, rather than relying on off-label use. Track the September 30, 2026 PDUFA date as the real inflection point; an approval would reset the standard of care for adolescent oHCM and create a downstream pull for genetic screening, monitoring, and specialty-pharmacy workflows in pediatric cardiology. This belongs in the FDA pediatric regulatory thread alongside earlier priority-review decisions (Kresladi, Otarmeni) as another case of specialized therapeutics reaching pediatric populations through FDA priority pathways.